ArticleBone marrow transplantation2020
Direct adjusted survival and cumulative incidence curves for observational studies.
Article in Bone marrow transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Evaluating distant recurrence-free survival and location of metastasis in HER2+ breast cancer by ER status.International journal of cancer · 2026Article
- Lifetime Risk of First Symptomatic ICH or Seizure in Familial Cerebral Cavernous Malformations: A Multicenter Patient Data Analysis.Neurology · 2025Article
- Doubly Robust Estimation of Marginal Cumulative Incidence Curves for Competing Risk Analysis.Statistics in medicine · 2025Article
- Prognostic nomogram and epidemiological analysis for lung atypical carcinoid: A SEER database and external validation study.Cancer medicine · 2024Article
- Association of Mediterranean diet with survival after breast cancer diagnosis in women from nine European countries: results from the EPIC cohort study.BMC medicine · 2023Article
- Independent and joint associations between the triglyceride-glucose index and NT-proBNP with the risk of adverse cardiovascular events in patients with diabetes and acute coronary syndrome: a prospective cohort study.Cardiovascular diabetology · 2023Article
- The association between body fatness and mortality among breast cancer survivors: results from a prospective cohort study.European journal of epidemiology · 2023Article
- Atrial fibrillation as a novel risk factor for retinal stroke: A protocol for a population-based retrospective cohort study.PloS one · 2023Article
- Standardised survival probabilities: a useful and informative tool for reporting regression models for survival data.British journal of cancer · 2022Article
- Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: A national cohort study.Journal of hospital medicine · 2022Article
- Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease.Blood advances · 2022Article
- Adjusted Survival Curves Improve Understanding of Multivariable Cox Model Results.The Journal of arthroplasty · 2021Article
- A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer.Advances in therapy · 2020Observational
- Precision medicine: Statistical methods for estimating adaptive treatment strategies.Bone marrow transplantation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
SERIES EDITORS' NOTE: Large randomized clinical trials testing the impact of subject-, disease- and transplant-related co-variates on outcomes amongst recipients of haematopoietic cell transplants are uncommon. For example, who is the best donor, which is the best pretransplant conditioning regimen or the best regimen to prevent or treat acute and/or chronic graft-versus-host disease. To answer these questions we often rely on analyses of data from large observational datasets such as those of the Center for International Blood and Marrow Transplant Research (CIBMTR) and the European Society for Blood and Marrow Transplantation (EBMT). Such analyses have proved extremely important in advancing the field. However, in contrast to randomized trials, we cannot be certain potentially important prognostic or predictive co-variates are balanced between cohorts selected for comparison from an observational dataset, a limitation which can lead to incorrect conclusions. In the typescript which follows the authours describe a method to adjust for known imbalances in co-variates and get a closer approximation of the truth. They give two examples, the impact of a new pretransplant conditioning regimen on disease-free survival (DFS) in subjects with Ewing sarcoma and the impact of donor-type on treatment-related mortality (TRM) and leukaemia relapse in subjects with acute leukaemia. Direct adjusted survival and cumulative incidence function (CIF) analyses are an important step forward. These analyses can be done using available statistical packages and we encourage readers to use them rather than reporting unadjusted analyses. Finally, we must emphasize direct adjustment can only be done for know prognostic or predictive co-variates, not unknown co-variates. Unknown co-variates will be balanced in randomized trials which is why we do them. So direct adjustment is an important step forward but not a perfect substitute for randomized trials. But any step forward is important. To quote Laozi: (A journey of a thousand miles begins with a single step).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.